A Multicenter, Randomized, Phase 2 Study to Assess the Feasibility, Safety and Efficacy of OTO-104 Given by Intratympanic Administration in Subjects at Risk for Ototoxicity From Cisplatin Chemotherapy Regimens in the Treatment of Cancer
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Dexamethasone (Primary)
- Indications Hearing loss
- Focus Therapeutic Use
- Sponsors Otonomy
- 14 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Sep 2017.
- 13 Sep 2017 Status changed from recruiting to discontinued according to an Otonomy media release.
- 13 Sep 2017 According to an Otonomy media release, all development activities for OTIVIDEX have been suspended including termination of ongoing clinical trials and pre-registration support efforts.